Abbott India posts Q3 FY24 PAT at Rs. 310.98 Cr

Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24

Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

Indian Red Cross Society and Cadila to launch training of 50,000 students for CPR and First Aid

The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr

Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023